Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.72 |
| ▸ | EED | O75530 | 18/20 | 0.72 |
| ▸ | RBBP4 | Q09028 | 18/20 | 0.72 |
| ▸ | SUZ12 | Q15022 | 18/20 | 0.72 |
| ▸ | AEBP2 | Q6ZN18 | 18/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213154 | 0.87 | EED (0.81) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20444945 | 0.85 | EZH2 (0.64) | EZH2 | |
| SCHEMBL20444914 | 0.84 | EZH2 (0.69) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20444553 | 0.84 | EZH2 (0.66) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20444944 | 0.84 | EZH2 (0.72) | EZH2 | |
| SCHEMBL16212596 | 0.84 | EED (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21544026 | 0.84 | EZH2 (0.58) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL16212935 | 0.83 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20444581 | 0.83 | EZH2 (0.61) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20444981 | 0.83 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214561-B2 | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2022-01-04 | — | — | US | disclosed |
| US-11214561-B2 | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2022-01-04 | — | — | US | disclosed |
| US-20190345139-A1 | HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| US-20190345139-A1 | HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| WO-2018137639-A1 | HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345139-A1 | HISTONE METHYLTRANSFERASE EZH2 INHIBITOR, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | EZH2, DOT1L, EHMT1 | EZH2 1/4885EED 13/4885RBBP4 293/4885 |
| US-11214561-B2 | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof | EZH2, DOT1L, EHMT1 | EZH2 1/4885EED 13/4885RBBP4 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.